{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-047688","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.972241+00:00","generated_at":"2026-06-10T01:35:26.273924+00:00","sec_items":["1.01","2.02","2.03","2.05","3.02","7.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bionano Genomics closes $80M convertible note financing with High Trail; plans 17% workforce reduction","bullets":["Entered securities purchase agreement to issue $45M registered and $35M private senior secured convertible notes due 2025; warrants to buy up to 21.66M shares at $3.1855.","Net proceeds estimated at $75.6M; proceeds used for working capital and general corporate purposes including R&D and capex.","Reduces headcount by ~66 employees (17% of full-time staff) as part of corporate reorganization to save ~$33M annually starting 2024.","Notes carry initial conversion price of ~$2.8638 per share; no regular interest; repayment at 115% of principal at maturity.","Issued press release announcing preliminary Q3 2023 results; specific figures not provided in filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-047688","json":"https://secwatch.observer/filing/0001140361-23-047688.json","markdown":"https://secwatch.observer/filing/0001140361-23-047688.md","text":"https://secwatch.observer/filing/0001140361-23-047688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123047688/0001140361-23-047688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123047688/ef20012228_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:35:26.273924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"100a9a009a908affa64298ffb98f46b740c10708","claim":"Bionano Genomics, Inc. incurred senior notes of up to an additional $25.0 million aggregate principal amount of Private Placement Notes with High Trail Special Situations LLC maturing 2025.","evidence_excerpt":"and together with the Registered Notes, the “Notes”). Pursuant to the Purchase Agreement, the Company also granted the Purchaser an option to purchase up to an additional $25.0 million aggregate principal amount of Private Placement Notes initially convertible into 8,729,813 shares of the Company’s common stock (the “Subsequently Purchased Notes”) and warrants","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123047688/0001140361-23-047688-index.htm","confidence":0.85,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"up to an additional $25.0 million aggregate principal amount of Private Placement Notes"},{"label":"Counterparty","value":"High Trail Special Situations LLC"},{"label":"Maturity","value":"2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"421c33be0a5a731c4fb7e0376a7fa0c0af1a48dd","claim":"Bionano Genomics, Inc. incurred senior notes of $35.0 million aggregate principal amount of senior secured convertible notes due 2025 with High Trail Special Situations LLC maturing 2025.","evidence_excerpt":"securities purchase agreement (the “Purchase Agreement”) with High Trail Special Situations LLC (the “Purchaser”) pursuant to which the Company agreed to issue and sell , (i) in a","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123047688/0001140361-23-047688-index.htm","confidence":0.85,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$35.0 million aggregate principal amount of senior secured convertible notes due 2025"},{"label":"Counterparty","value":"High Trail Special Situations LLC"},{"label":"Maturity","value":"2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"b1dea2c7cdd2b40572cc6cdb9dd4ddea7e655ce0","claim":"Bionano Genomics, Inc. incurred senior notes of $45.0 million aggregate principal amount of senior secured convertible notes due 2025 with High Trail Special Situations LLC maturing 2025.","evidence_excerpt":"securities purchase agreement (the “Purchase Agreement”) with High Trail Special Situations LLC (the “Purchaser”) pursuant to which the Company agreed to issue and sell , (i) in a","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123047688/0001140361-23-047688-index.htm","confidence":0.85,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$45.0 million aggregate principal amount of senior secured convertible notes due 2025"},{"label":"Counterparty","value":"High Trail Special Situations LLC"},{"label":"Maturity","value":"2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"893a4e3d8807a6dfb70ef14040faabc862709c14","claim":"Bionano Genomics, Inc. reported preliminary financial results for the third quarter of 2023.","evidence_excerpt":"On October 11, 2023, the Company issued a press release announcing certain preliminary performance results for the third quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123047688/0001140361-23-047688-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"cfbff1e7e17004dc37d7397bda372fa66e20f14e","claim":"Bionano Genomics, Inc. entered into Securities Purchase Agreement with High Trail Special Situations LLC valued at $45.0 million aggregate principal amount of senior secured convertible notes due 2025; $35.0 million (effective 2023-10-11).","evidence_excerpt":"On October 11, 2023, Bionano Genomics, Inc. (the “Company,” “we,” “us,” and “our”) entered into a securities purchase agreement (the “Purchase Agreement”) with High Trail Special Situations LLC (the “Purchaser”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123047688/0001140361-23-047688-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"High Trail Special Situations LLC"},{"label":"Value","value":"$45.0 million aggregate principal amount of senior secured convertible notes due 2025; $35.0 million"},{"label":"Effective","value":"2023-10-11"}],"fact_type":"material_agreement"},{"claim_id":"562c657923ce365b005f2374e7d0896f5a34019a","claim":"Bionano Genomics, Inc. announced a restructuring with charges of approximately $0.8 million to $1.0 million affecting corporate reorganization plan (approximately 66 employees, which represents 17% of its full-time employees).","evidence_excerpt":"in stock-based compensation, and an expected reduction in cost of goods sold of approximately $1.4 million. The Company expects to incur non-recurring charges of approximately $0.8 million to $1.0 million related to the Reduction, consisting primarily of cash severance payments, employee benefits and related costs. Of the total charges, substantially all charges","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123047688/0001140361-23-047688-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.8 million to $1.0 million"},{"label":"Affected area","value":"corporate reorganization plan"},{"label":"Headcount","value":"approximately 66 employees, which represents 17% of its full-time employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}